ENDOLOGIX INC /DE/
Healthcare · Surgical & Medical Instruments & Apparatus · DE · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | |
|---|---|---|---|---|---|---|
| Revenue | $35.6M | $42.3M | $181.2M | $192.9M | — | — |
| Operating income | −$42.5M | −$68.2M | −$41.8M | −$95.1M | −$52.9M | −$29.1M |
| Net income | −$22.0M | −$19.8M | −$66.4M | −$154.7M | −$50.4M | −$32.4M |
| Total assets | $307.2M | $293.1M | $365.0M | $359.7M | $331.1M | $248.2M |
| Total liabilities | $243.3M | $253.4M | $290.0M | $246.9M | $227.7M | $124.1M |
| Equity | $63.9M | $39.6M | $75.1M | $112.8M | $103.3M | $124.2M |
| EPS (diluted) | — | — | — | — | $-0.17 | $0.08 |
| Shares out. | 10.3M | 83.7M | 82.9M | 81.7M | 67.2M | 63.9M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2019- Operating margin
- −119.5%
- Net margin
- −61.9%
- Return on equity
- −34.5%
- Return on assets
- −7.2%
- Return on capital (ROCE)
- −16.9%
- Liabilities / assets
- 79.2%
- Debt / equity
- 3.81×
- Book value / share
- $6.17
- Revenue growth (YoY)
- −15.8%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2019- Altman Z″ (distress)
- -6.90distress
- Accruals / assets
- 2.5%clean
- Piotroski F-Score
- 3/9weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 2 severe● 5 warning● 1 good- Altman Z″ in the distress zone
- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Operating losses (negative operating margin)
- Reported a net loss
- Revenue declined year-over-year
- High leverage (liabilities > 70% of assets)
- Negative operating cash flow
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Kmissed a reporting deadline ↗Mar 19, 2019
- NT 10-Kmissed a reporting deadline ↗Mar 1, 2013
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
Material events
SEC Form 8-K · most recent- Other material eventOct 1, 2020
- Other material eventSep 22, 2020
- Entered a material agreement · Bankruptcy or receivership · New financial obligation · Debt acceleration / triggering event · Delisting / listing-standard noticeJul 9, 2020
- Other material eventJul 6, 2020
- Entered a material agreementJul 1, 2020
- Director / officer changeJun 24, 2020
- Director / officer changeJun 19, 2020
- Entered a material agreementJun 15, 2020
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Event-driven situations (2)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.